U-Neuron Biomedical

U-Neuron Biomedical Forward P/E

The Forward P/E Ratio of U-Neuron Biomedical (6973.TWO) as of Oct 16, 2026 is -25.66. In the previous year, Forward P/E Ratio was -18.12 — a change of 41.56% (lower).

Forward P/E

-25.66

YoY

41.56%

Last updated:

Forward P/E Ratio of U-Neuron Biomedical is 2024 -25.66 . Forward P/E Ratio of U-Neuron Biomedical was 2023 -18.12 . It decreases by 41.56% lower compared to the previous year.

The U-Neuron Biomedical Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2021
-136.66 TWD
Jan 1, 2022
-35.64 TWD
Jan 1, 2023
-18.12 TWD
Jan 1, 2024
-25.66 TWD
The U-Neuron Biomedical Forward P/E history
YEARForward P/EYoY
-25.66+41.56%
-18.12-49.15%
-35.64-73.92%
-136.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc, headquartered in Taipei, Taiwan, operates in the Health Care sector within the Biotechnology industry. The company, listed on 20 July 2023, develops cosmetics, health care consumer products, and new drugs. Its drug development focuses on allogeneic amniotic fluid stem cells for applications like erectile dysfunction (UA002) and dry eye (UB003). Cosmetic products, featuring deer amniotic fluid stem cell derivatives, include anti-aging masks, essences, and creams for repair and hydration, primarily sold domestically in Taiwan. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about U-Neuron Biomedical stock

Forward P/E Ratio of U-Neuron Biomedical is -25.66 in 2024.

Forward P/E Ratio of U-Neuron Biomedical changed from -18.12 to -25.66, representing a 41.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's U-Neuron Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — U-Neuron Biomedical

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — U-Neuron Biomedical